PPARγ ligands are prescribed and have been studied to improve metabolic pathologic outcomes in type II diabetes, dyslipidemia, and nonalcoholic steatohepatitis [54,55]. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatohepatitis.